首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   312731篇
  免费   17397篇
  国内免费   663篇
林业   24849篇
农学   14360篇
基础科学   3014篇
  47580篇
综合类   36695篇
农作物   17544篇
水产渔业   18621篇
畜牧兽医   135809篇
园艺   6520篇
植物保护   25799篇
  2020年   3011篇
  2019年   3773篇
  2018年   4659篇
  2017年   5097篇
  2016年   5291篇
  2015年   4621篇
  2014年   6024篇
  2013年   16620篇
  2012年   8485篇
  2011年   10958篇
  2010年   8458篇
  2009年   8799篇
  2008年   10203篇
  2007年   9456篇
  2006年   9599篇
  2005年   8714篇
  2004年   8521篇
  2003年   8362篇
  2002年   7578篇
  2001年   8940篇
  2000年   8617篇
  1999年   7458篇
  1998年   4410篇
  1997年   4329篇
  1996年   4020篇
  1995年   4731篇
  1994年   4149篇
  1993年   3820篇
  1992年   5790篇
  1991年   6045篇
  1990年   5832篇
  1989年   5832篇
  1988年   5207篇
  1987年   5209篇
  1986年   5104篇
  1985年   5236篇
  1984年   4615篇
  1983年   4226篇
  1982年   3308篇
  1981年   3128篇
  1980年   3038篇
  1979年   3980篇
  1978年   3451篇
  1977年   3099篇
  1976年   2924篇
  1975年   2944篇
  1974年   3206篇
  1973年   3230篇
  1972年   2928篇
  1971年   2829篇
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
131.
132.
To determine whether turkey herpesvirus (HVT) impairs the aspecific and specific defense against an avian pneumovirus (APV) infection, specific-pathogen-free turkeys were inoculated at 7 days of age with HVT and 1, 5, or 7 wk later with APV. Clinical signs, APV replication, and development of antibodies against APV were evaluated. No differences were found between the birds that received both HVT and APV and those that received only APV.  相似文献   
133.
134.
OBJECTIVE: To determine epidemiologic, clinical, and pathologic characteristics of inflammatory mammary carcinoma (IC) in dogs. DESIGN: Retrospective study. ANIMALS: 33 dogs with IC and 153 dogs with malignant mammary tumors other than IC. PROCEDURES: Medical records were reviewed, and signalment, history, physical examination findings, and results of thoracic radiography and necropsy were obtained. RESULTS: 33 of 436 (7.6%) dogs examined at a veterinary teaching hospital because of dysplasia or tumors of the mammary glands and 33 of 186 (17.7%) dogs with at least 1 malignant tumor had IC. Thirty-two of the 33 dogs were sexually intact. Dogs with IC were significantly older than were dogs with other malignant mammary tumors, and in dogs with IC, the tumor was initially noticed a mean of 52 days after the beginning of the last observed estrus, whereas in dogs with other mammary tumors, the tumor was initially noticed a mean of 137 days after the beginning of the last observed estrus. Dogs with IC were more likely to be anorectic and to have generalized weakness, weight loss, and thoracic metastases. Dogs with IC survived a mean of 25 days with palliative treatment. Histologically, involvement of dermal lymphatic vessels was identified in 14 of 19 (74%) dogs with IC. Two clinical forms of IC (primary and secondary) were identified. Dogs with primary IC had a worse clinical condition. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that IC is an uncommon but distinct entity in dogs. A histologic finding of dermal lymphatic involvement should be considered a hallmark for the pathologic diagnosis of IC in dogs.  相似文献   
135.
136.
An experiment was designed to evaluate the effects of estradiol‐17β (E17β) on follicular wave dynamics and ovulatory response in Holstein heifers receiving either a progestogen ear‐implant (Crestar®; Intervet International b.v. Boxmeer, The Netherlands) or an intravaginal progesterone‐releasing device [controlled internal drug release‐bovine device (Eazibreed, CIDR‐B®; Bodinco BV, Alkmaar, The Netherlands)]. For comparison, another group of heifers was also synchronized using Crestar plus an injection of estradiol valerate (EV) and norgestomet as recommended by the pharmaceutical company. Twenty 20–22‐month‐old cycling Holstein heifers were allocated to one of the following treatment groups at random stages of the oestrous cycle: (I) simultaneous insertion of Crestar and intramuscular injection of 3 mg norgestomet and 5 mg EV (Crestar 9 + EV 9); (II) simultaneous insertion of Crestar and intramuscular injection of 5 mg E17β (Crestar 9 + E17β 9); (III) insertion of Crestar followed 2 days later by intramuscular injection of 5 mg E17β (Crestar 9 + E17β 7); or (IV) insertion of CIDR‐B device followed 2 days later by intramuscular injection of 5 mg E17β (CIDR 9 + E17β 7). The CIDR‐B or Crestar implants were removed after 9 days and all heifers received 500 μg Cloprostenol (Estrumate®, Pitman‐Moore Nederland BV, Houten, The Netherlands). Ovarian ultrasonographic examinations were performed once daily during the synchronization period using a B‐mode scanner equipped with a 7.5 MHz linear‐array transrectal transducer. In addition, heifers were scanned every 12 h after implant/device withdrawal until 3 days after ovulation in order to monitor follicular activity, detect ovulation and subsequent early luteal formation. Detection of oestrus was performed every 6 h for 4 days after device/implant removal. Oestrus was observed 24–32 h before ovulation in all heifers. The mean hours interval from treatment withdrawal to ovulation was not significantly different (84.0 ± 16.5, 77.6 ± 4.1, 73.6 ± 4.1 and 64.0 ± 4.4 h for treatments I, II, III and IV, respectively; p > 0.1). However, the variance for heifers treated with EV + norgestomet was significantly larger (Levene’s Test; p < 0.01) than those treated with E17β. All E17β treatments resulted in dominant follicle suppression and a new wave emerged 4.1 days after treatment compared with 6.6 days for the EV + norgestomet treatment (p < 0.05). The time from emergence of the new ovulatory wave to ovulation was longer for the new wave that emerged after E17β treatment (9.2 ± 0.3 days) than after EV + norgestomet treatment (6.9 ± 0.4 days; p < 0.05). The results of this study suggest that the four treatments used were effective in inducing synchronous behavioural oestrus and ovulation. However, a higher degree of oestrus and ovulation synchrony was observed in heifers treated with E17β than in heifers treated with EV + norgestomet. Synchronization treatments with exogenous E17β or EV + norgestomet at the time of progestin device insertion (Crestar or CIDR‐B) or 2 days later in heifers can regulate a different emergence pattern of ovarian follicular development in randomly cyclic heifers. The E17β was effective in inducing follicular suppression and resulted in the consistent emergence of a new follicular wave.  相似文献   
137.
Grain yield and yield components (grains per ear, grain weight, 1000-grain weight, ear weight, ear seed ratio and dry matter partitioning between ear and seed) were examined in a wheat genotype (PBW-343) with well-filled grains and a Triticale genotype (DT-46) with poorly filled grains (showing grain shrivelling) grown in pots. Six days after anthesis (DAA), benzyladenine (BA) @2 µg ear−1 and abscisic acid (ABA) @4 µg ear−1 were injected at the base of the mother shoot ear in both species. It was observed that, in both wheat and Triticale , BA increased the grain weight, grain number and partitioning of dry matter between ear and seed, whereas ABA decreased the grain weight, grain number and dry matter partitioning between ear and seed. However, these decreases were slower in Triticale than in wheat. BA treatment increased the grain dry matter accumulation, which in turn resulted in better filling of grains and increased the grain weight in both wheat and Triticale . The average grain weight of Triticale was lower than that of wheat. Thus, it appears that variation in grain weight between wheat and Triticale might be due to different availabilities of growth-promoting phytohormones such as cytokinins and assimilates.  相似文献   
138.
139.
Twelve (54.5%) of 22 free-roaming dogs in Ishigaki Island had tick infestation identified as Rhipicephalus sanguineus. There were 121 ticks recovered and consisted of 28 females, 58 males, 22 nymphs and 3 larvae. Infection of dogs possibly with canine ehrlichial pathogens was examined by both indirect immunofluorescence assay and polymerase chain reaction (PCR). Two dogs of the 13 examined were sero-positive for the human granulocytic ehrlichia agent, and one of two dogs was PCR positive for Ehrlichia platys. This dog had platelet numbers slightly lower than normal value, however, no morulae were found within platelet on peripheral blood smear stained with Giemsa.  相似文献   
140.
OBJECTIVE: To evaluate trends in feedlot cattle mortality ratios over time, by primary body system affected, and by type of animal. DESIGN: Retrospective cohort study. ANIMALS: Approximately 21.8 million cattle entering 121 feedlots in the United States during 1994 through 1999. PROCEDURES: Yearly and monthly mortality ratios were calculated. Numbers of deaths were modeled by use of Poisson regression methods for repeated measures. Relative risks of death over time and by animal type were estimated. RESULTS: Averaged over time, the mortality ratio was 12.6 deaths/1,000 cattle entering the feedlots. The mortality ratio increased from 10.3 deaths/1,000 cattle in 1994 to 14.2 deaths/1,000 cattle in 1999, but this difference was not statistically significant (P = 0.09). Cattle entering the feedlots during 1999 had a significantly increased risk (relative risk, 1.46) of dying of respiratory tract disorders, compared with cattle that entered during 1994, and respiratory tract disorders accounted for 57.1% of all deaths. Dairy cattle had a significantly increased risk of death of any cause, compared with beef steers. Beef heifers had a significantly increased risk of dying of respiratory tract disorders, compared with beef steers. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that although overall yearly mortality ratio did not significantly increase during the study, the risk of death attributable to respiratory tract disorders was increased during most years, compared with risk of death during 1994. The increased rates of fatal respiratory tract disorders may also reflect increased rates of non-fatal respiratory tract disorders, which would be expected to have adverse production effects in surviving animals.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号